The European Federation of Crohn’s and Ulcerative Colitis Associations (EFCCA), an umbrella organization that represents 34 patient associations around the world, recently released a report on healthcare inequities among nations and regions. In the report, the EFCCA identified disparities in access to biologics and biosimilars.
The European Federation of Crohn’s and Ulcerative Colitis Associations (EFCCA), an umbrella organization that represents 34 patient associations around the world, recently released a report on healthcare inequities among nations and regions. In the report, the EFCCA identified disparities in access to biologics and biosimilars for the treatment of inflammatory bowel disease (IBD).
To compile the report, EFCCA surveyed 32 national associations about the availability and coverage of biologics and biosimilars in their respective nations. Associations participating in the survey represented Argentina, Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Israel, Italy, Malta, New Zealand, Norway, Poland, Portugal, Romania, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, and the United Kingdom.
Responders reported that adalimumab (Humira) is approved to treat IBD diagnoses in all of the participating countries. In addition:
Reference infliximab (Remicade) is also approved to treat IBD in each of the participating countries.
Biosimilar infliximab, Inflectra, was reported as approved to treat IBD in 27 nations (84%).
Interestingly the same molecule, when marketed as Remsima, had differences in availability and coverage compared with the Inflectra-branded biosimilar. Respondents indicated that the Remsima-branded drug was approved for IBD in 25 nations (78%) and was fully covered in 12 nations (48%). However, only 11 nations (44%) reported preconditions for use.
“The outcomes of this survey also show clearly that access to new innovative therapies in different countries is far from equal,” write the report’s authors. “Apart from the differences between countries, there are also regional differences within the same country; these may be due to geographical or economic issues. Although it is understandable that access to health care services…can be very different, it puts patients in highly unequal positions.”
Targeted Reimbursement Encourages Oncology Biosimilar Use
May 7th 2025Incentivizing physicians with modest financial bonuses may seem like a small step, but in Japan’s outpatient oncology setting, it helped push trastuzumab biosimilars toward broader adoption, demonstrating how even limited reimbursement reforms can reshape prescribing behavior under the right conditions.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships
April 29th 2025Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.